FDA approval of ICOTYDE™ (icotrokinra) ushers in new era for first-line systemic treatment of plaque psoriasis with a targeted oral peptide

Ce que nous avons tiré de cette source

The claims Via News extracted from this document. We point to the source; we don't replace it.

• At Johnson & Johnson, we are harnessing our scientific expertise to transform cutting-edge science into meaningful solutions for patients. ICOTYDE is a fundamentally different treatment with the potential to redefine what physicians and patients can expect from psoriasis treatment

  60% confidence

• ICOTYDE delivers something unique in psoriasis treatment – combining skin clearance with a favorable safety profile in a once-daily pill, making it an easy addition to a patient's routine

  60% confidence

• We're proud to bring this game-changing innovation to the market, marking a transformative shift in plaque psoriasis management that empowers patients and clinicians to reach their treatment goals

  60% confidence

• With the FDA approval of ICOTYDE, Johnson & Johnson is setting a new standard for the treatment of moderate-to-severe plaque psoriasis

  60% confidence

• ICOTYDE met all primary efficacy endpoints and demonstrated a favorable safety profile across four Phase 3 studies including 2,500 patients

  60% confidence

• In the head-to-head superiority studies, approximately 70% of patients achieved clear or almost clear skin (IGA 0/1) and 55% of patients achieved a PASI 90 response at Week 16

  60% confidence

• The approval of ICOTYDE represents a pivotal moment for people with plaque psoriasis

  60% confidence

• Finding the right treatment can take time, during which people with psoriatic disease should be considering multiple factors from efficacy to safety to how the treatment fits into their everyday life

  60% confidence

• With new guidance from the International Psoriasis Council clarifying when to move beyond cycling on topical treatments to systemic therapy, an innovative option like ICOTYDE is a potential game-changer for many adult and adolescent patients

  60% confidence

• Transition to systemic therapy should occur if two cycles of topical medications applied for four weeks fail to bring meaningful improvement

  60% confidence

• Rates of adverse reactions for ICOTYDE treated patients were within 1.1% of placebo through Week 16 and no new safety signals were identified through Week 52

  60% confidence

• The approval of a novel systemic therapy changes the conversation about treatment options for our community

  60% confidence